Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib in Delaying the Progression of Alzheimer's Disease
NCT00006187Phase 3Terminated
- Sponsor
- Merck & Co.
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rofecoxib in Alzheimer's disease (AD) (3 arms), sponsored by Merck & Co. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 12 months, Clinician's Interview-Based Impression of Change Plus Caregiver Input at 12 months and 1 more. Status: terminated.
02
Drugs
rofecoxib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00006187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006187.